Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: Results of the OPTIMAX trial

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 173-180

  Mourad, Jean Jacques ^a   Nguyen, Viet ^a   Lopez Sublet, Marilucy ^a   Waeber, Bernard ^b  

^a AVICENNE HOSPITAL   (France)

^b Division de Physiopathologie Clinique   (Switzerland)

Author keywords

Blood pressure normalization; Combination therapy; Indapamide; Perindopril; Risk factors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PREDICTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INDAPAMIDE; MIDDLE AGED; PERINDOPRIL; RISK FACTORS; TREATMENT OUTCOME;

EID: 34249862452     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ADVANCE management committee. 2001. Study rationale and design of ADVANCE: action in diabetes and vascular disease-Preterax and Diamicron MR controlled evaluation. Diabetologia, 44:1118-20.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2003. Diuretic versus α-blocker as first-step antihypertensive therapy. Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension, 42:239-46.
3. Amar J, Vaur L, Perret M, et al. 2002. On behalf of the PRATIK study investigators. Hypertension in high-risk patients: beware ofthe under-use of effective combination therapy (results of the PRATIK study). J Hypertens, 20:779-84.
4. Asmar RG, London GM, O'Rourke ME, et al. 2001. Improvement in blood pressure, arterial stiffhess and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension, 38:922-6.
5. Chalmers J, Castaigne A, Morgan T, et al. 2000. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/ diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens, 18:327-37.
6. Chamontin B, Lang T, Vaisse B, et al. 2001. [Regional management of arterial hypertension in France. Report of a survey of general practitioners]. Arch Mal Coeur Vaiss, 94:823-7.
7. Chobanian AV, Bakris GL, Black HR, et al. 2003. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 289:2560-72.
8. Cushman WC, Ford CE, Cutler JA, et al. 2002. Success and predictors of blood pressure control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich), 4:393-404.
9. Dahlof B, Gosse P, Gueret P, et al. 2005. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens, 23:2063-70.
10. de Luca N, Mallion JM, O'Rourke MF, et al. 2004. Regression of left ventricular mass in hypertensive patients treated with perindopril/ indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens, 17:660-7.
11. [ESH-ESC] 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003. J Hypertens, 21:1011-53.
12. Franklin SS, Larson MG, Khan SA, et al. 2001. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation, 103:1245-9
13. Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351:1755-62.
14. Haute Autorité de Santé. 2005. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle (Management of adult patients with essential arterial hypertension. Recommendations) - Recommendations. 2005 Update [online]. Accessed:July 2006. URL: http://www.sfhta.org/pdf/2RecoHTA2005.pdf.
15. The Heart Outcomes Prevention Evaluation Study Investigators. 2000. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 355:253-9.
16. Holzgreve H, Risler T, Trenkwalder P. 2006. Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study. Curr Med Res Opin, 22:1849-58.
17. Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet, 363:2022-31.
18. Kawata T, Masao D, Rei H, et al. 2006. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: Comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. Am Heart J, 151:798.e9-798.e15.
19. London CM, Asmar RG, O'Rourke M, et al. 2004. Mechanism(s) of selective Systolic Blood pressure reduction after a low-dose combination of perindopril/Indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol, 43:92-9.
20. Mancia G, Pessina AC, Trimarco B, et al. SILVIA (Studio Italiano Longitudinale sulla valutazione della Ipertensione Arteriosa nel 2000) Study group. 2004. Blood pressure control according to new guidelines targets in low-to high-risk hypertensives managed in specialist practice. J Hypertens, 22:2387-96.
21. Materson BJ, Reda DJ, Cushman WC, et al. 1995. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens, 9:791-6.
22. Mogensen CE, Viberti G, Halimi S, et al. 2003. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER. Hypertension, 41:1063-71.
23. Mourad JJ, Hanon O, Deverre JR. 2003. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/ diuretic therapy: a pilot PET study. J Renin Angiotens Aldoster Syst, 4:94-5.
24. Mourad JJ, Waeber B, Zannad F, et al. 2004. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens, 22:2379-86.
25. Renaud IM, Chainey A, Belair MF, et al. 2004. Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination. Fundament Clin Pharmacol, 18:437-47.
26. Roux O, Chapellier M, Czernichow S, et al. 2006. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press, 15:6-13.
27. Waeber B, Mourad JJ. 2006. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens, 19:985-6.
28. Williams B, Lacy PS, Thom SM, et al. 2006. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113:1213-25.
29. Wolf-Maier K, Cooper RS, Kramer H, et al. 2004. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension, 43:10-17.